Interview 21 May 2018
Engineering Red Blood Cells to Fight the Most Severe Cancers
Our very own red blood cells could soon become a treatment for some of the most severe forms of cancer; After a long journey of ups and downs, Erytech is…
Blood cancer
- Latest Posts
News and Trends 19 Apr 2018
“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“
Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. …
Startup Scout 2 Mar 2018
This Spanish Biotech Is Developing Stem-Cell Targeted Leukemia Treatments
This week, we're in Barcelona, Spain, to visit Leukos Biotech, whose goal is to develop new treatments and diagnostic tools for Leukaemia. [caption id="attachment_56204" align="alignnone" width="800"] Visit our map to…
News and Trends 22 Jan 2018
Novartis Takes Genmab’s Leukemia Drug Off the Market
Genmab's leukemia drug will be available around the world through compassionate use programs, while it will continue to be marketed as normal in the US. Blockbuster drug owner Genmab developed Arzerra for the treatment…
ADVERTISEMENT
Best in Biotech 18 Dec 2017
Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017
Now that we've got the bad news out of the way, we're here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months.…
News and Trends 13 Dec 2017
Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment
Data presented at ASH 2017 shows that Servier and Pfizer's UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR-T cells. CAR-T cell therapy has…
News and Trends 11 Dec 2017
New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients
ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in…
News and Trends 4 Dec 2017
Dutch Bone Marrow Transplant for Blood Cancer could get rid of Donor Matching
Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors suitable for bone marrow transplant to treat blood cancer. From its Amsterdam headquarters, Kiadis Pharma…
News and Trends 17 Nov 2017
Welcome to the Blockbuster Club, Genmab!
Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a great example for other European biotechs to follow. Genmab has officially joined the elite of…
News and Trends 14 Nov 2017
This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected
Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form…
ADVERTISEMENT
News and Trends 19 Oct 2017
The FDA Approves a Second CAR-T Therapy, Cheaper than Novartis’
Gilead's CAR-T cell therapy Yescarta has been approved by the FDA, making it the first competitor for Novartis' CAR-T Kymriah. Yescarta (axicabtagene ciloleucel, or axi-cel for short) has become the second CAR-T…
News and Trends 21 Jul 2017
Roche Abandons Spanish Cancer Epigenetics Drug
Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified…
News and Trends 28 Jun 2017
UPDATE: The First Off-the-Shelf CAR-T Cancer Therapy has Entered the Clinic
Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial in Acute Myeloid Leukemia. Update (07/02/2017): the FDA has granted Cellectis IND approval to start…
Interview 22 May 2017
Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer
Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of…
News and Trends 13 Apr 2017
Next-Gen Cancer Antibody Technology from Germany enters the Clinic
Apogenix' partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has…
News and Trends 6 Apr 2017
UPDATE: Norwegian Stock Exchange hits Record Biotech IPO
UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the…
ADVERTISEMENT
Interview 23 Mar 2017
Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics
Located right here in Barcelona, Oryzon is one of the world's few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach. Since its foundation in 2000,…
News and Trends 1 Mar 2017
Swedish Oncology Biotech makes a Large IPO for its Peptides
The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and…
News and Trends 21 Feb 2017
New Immunotherapy Candidate receives FDA Fast Track Designation
Cell Medica's Orphan Drug CMD-003 has received fast track designation by the FDA to advance immunotherapy of patients with Epstein Bar Virus (EBV)-associated malignancies. The FDA's fast track designation has been designed to…
News and Trends 6 Feb 2017
French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial
Innate Pharma's checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company's stock. When the stock market opened this…
